Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1DLBCL 1Carcinoma 1

Interventions

Etoposide 18Carboplatin 18pembrolizumab 15Nivolumab 11Cisplatin 11atezolizumab 8Topotecan 8Irinotecan 7Temozolomide 6Paclitaxel 5PM 01183 5Ipilimumab 5Gemcitabine 5olaparib 4Radiotherapy 4Docetaxel 4surufatinib 3durvalumab 3carfilzomib 3Bevacizumab 3veliparib 2trilaciclib 2sacituzumab govitecan 2rovalpituzumab tesirine 2obatoclax 2niraparib 2navitoclax 2lorvotuzumab mertansine 2lenvatinib 2fluzoparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × vistusertib × Clear all
NCT03366103 2023-10-17

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 14 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡